Posts Feed
Comments Feed

Archive for the 'Bipolar' Category

Repligen Initiates Phase 2b Clinical Trial Of RG2417 In Bipolar Disorder

Nov 7th 2008Drug InformationBipolar

Repligen Corporation (Nasdaq: RGEN) announced that the Company has initiated a Phase 2b clinical trial to evaluate the use of RG2417, an oral formulation of uridine, in patients with bipolar depression. This Phase 2b study is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or placebo twice daily for eight weeks.

More: continued here

No Comments »

One In Five Hospital Admissions Are For Patients With Mental Disorders, USA

Nov 2nd 2008Drug InformationBipolar

About 1.4 million hospitalizations in 2006 involved patients who were admitted for a mental illness, while another 7.1 million patients had a mental disorder in addition to the physical condition for which they were admitted, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The 8.5 million hospitalizations involving patients with mental illness represented about 22 percent of the overall 39.5 million hospitalizations in 2006.

More: continued here

No Comments »

Bipolar Disorder Involves A Lower Quality Of Both Mental And Physical Life, Even In Periods Of Normality

Nov 2nd 2008Drug InformationBipolar

A study carried out in the Institute of Neurosciences of the University of Granada (Spain) and the Mental Health Unit of the Hospital Neurotraumatológico of Jaen (Spain) has evaluated the quality of life of patients suffering from bipolar disorder (BD), in comparison with the general population, and which variables are connected with patients with a lower quality of life.

More: continued here

No Comments »

« Prev - Next »

1